Zentalis Pharmaceuticals (ZNTL) Competitors $1.34 -0.04 (-2.90%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.36 +0.01 (+1.12%) As of 08/1/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. CMPS, ETON, AQST, SNDL, ARCT, ITOS, VIGL, CYRX, HUMA, and ATXSShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include COMPASS Pathways (CMPS), Eton Pharmaceuticals (ETON), Aquestive Therapeutics (AQST), SNDL (SNDL), Arcturus Therapeutics (ARCT), iTeos Therapeutics (ITOS), Vigil Neuroscience (VIGL), CryoPort (CYRX), Humacyte (HUMA), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Its Competitors COMPASS Pathways Eton Pharmaceuticals Aquestive Therapeutics SNDL Arcturus Therapeutics iTeos Therapeutics Vigil Neuroscience CryoPort Humacyte Astria Therapeutics Zentalis Pharmaceuticals (NASDAQ:ZNTL) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment. Which has more risk and volatility, ZNTL or CMPS? Zentalis Pharmaceuticals has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Which has higher earnings and valuation, ZNTL or CMPS? COMPASS Pathways has lower revenue, but higher earnings than Zentalis Pharmaceuticals. COMPASS Pathways is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$67.43M1.43-$165.84M-$3.13-0.43COMPASS PathwaysN/AN/A-$155.12M-$1.99-2.18 Do institutionals & insiders have more ownership in ZNTL or CMPS? 46.2% of COMPASS Pathways shares are held by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is ZNTL or CMPS more profitable? Zentalis Pharmaceuticals' return on equity of -65.48% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -65.48% -51.05% COMPASS Pathways N/A -85.64%-59.63% Does the media refer more to ZNTL or CMPS? In the previous week, COMPASS Pathways had 6 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 8 mentions for COMPASS Pathways and 2 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.05 beat COMPASS Pathways' score of 0.14 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ZNTL or CMPS? Zentalis Pharmaceuticals currently has a consensus target price of $8.37, indicating a potential upside of 524.38%. COMPASS Pathways has a consensus target price of $17.00, indicating a potential upside of 291.71%. Given Zentalis Pharmaceuticals' higher probable upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than COMPASS Pathways.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50COMPASS Pathways 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 SummaryCOMPASS Pathways beats Zentalis Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.29M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.4317.6228.7823.81Price / Sales1.43179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book0.288.508.275.54Net Income-$165.84M-$55.06M$3.25B$259.28M7 Day Performance-8.84%-3.99%-3.70%-4.64%1 Month Performance8.06%9.58%4.34%4.41%1 Year Performance-62.88%6.70%25.90%17.95% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals2.0984 of 5 stars$1.34-2.9%$8.37+524.4%-64.7%$99.29M$67.43M-0.43160News CoveragePositive NewsUpcoming EarningsGap DownCMPSCOMPASS Pathways2.7759 of 5 stars$4.34+0.2%$17.00+291.7%-36.9%$406.05MN/A-2.18120News CoveragePositive NewsEarnings ReportAnalyst ForecastETONEton Pharmaceuticals1.8914 of 5 stars$15.03-2.4%$29.67+97.4%+289.3%$403.08M$48.33M-83.5020News CoverageUpcoming EarningsAQSTAquestive Therapeutics1.7153 of 5 stars$4.00-3.6%$10.14+153.6%+6.4%$397.31M$54.23M-6.78160Upcoming EarningsSNDLSNDL2.6343 of 5 stars$1.50-1.0%$4.00+166.7%-25.3%$394.17M$671.81M-5.172,516Trending NewsEarnings ReportAnalyst RevisionARCTArcturus Therapeutics3.0347 of 5 stars$14.38-3.7%$54.00+275.5%-43.0%$389.99M$152.31M-5.68180Positive NewsITOSiTeos Therapeutics2.9503 of 5 stars$10.11-0.6%$15.64+54.7%-42.2%$386.95M$35M-3.3390Upcoming EarningsVIGLVigil Neuroscience2.7973 of 5 stars$8.06+0.1%$10.80+34.0%+100.7%$384.38MN/A-3.9340Negative NewsShort Interest ↑CYRXCryoPort2.1548 of 5 stars$7.65-2.5%$11.11+45.2%-16.4%$383.55M$232.13M-3.271,186Upcoming EarningsHUMAHumacyte1.9379 of 5 stars$2.47-2.4%$11.71+374.3%-73.5%$383.15M$1.57M-3.58150News CoverageGap DownATXSAstria Therapeutics2.4034 of 5 stars$6.63-0.3%$30.00+352.5%-41.4%$374.16MN/A-3.5530News CoveragePositive News Related Companies and Tools Related Companies CMPS Competitors ETON Competitors AQST Competitors SNDL Competitors ARCT Competitors ITOS Competitors VIGL Competitors CYRX Competitors HUMA Competitors ATXS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZNTL Stock Alerts